Abstract
Synovial sarcoma have two histological subtypes, biphasic and monophasic, defined respectively by the presence or absence of glandular epithelial differentiation. To develop histological biomarkers for synovial sarcoma subtypes, we examined the proteomic profile using two-dimensional difference gel electrophoresis. We identified 29 protein spots whose intensity was statistically different between the monophasic (15 cases) and biphasic (9 cases) subtypes (p <0.01). Mass spectrometric protein identification demonstrated that these 29 spots corresponded to 24 distinct gene products involved in cytoskeletal organization, trsnscription/translation, protein/collagen binding, and ion transport, as well as structural constituents of the epidermis. Two of the 29 spots derived from glutathione S-transferase P (GST-P1) had higher intensity in biphasic type. Immunohistochemistry on additional 42 synovial sarcoma cases revealed that positive expression of GST-P1 was observed in 10 of 12 biphasic (83.3%), in 4 of 27 monophasic (14.8%) and in 1 of 3 poorly differentiated synovial sarcomas (p = 0.0002). Among the clinico-pathological parameters examined, GST-P1 expression significantly correlated only with the histological subtype. GST-P1 had more discriminative power than the status of fusion genes SYT-SSX1 and SYT-SSX2, previously reported to be correlated with the histological subtype. These results establish GST-P1 as a histological biomarker candidate for synovial sarcoma differentiation into subtypes.
| Original language | English |
|---|---|
| Pages (from-to) | 623-634 |
| Number of pages | 12 |
| Journal | Proteomics - Clinical Applications |
| Volume | 3 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 2009 |
Fingerprint
Keywords
- 2-D DIGE
- GST-P1
- Proteomics
- Synovial sarcoma
ASJC Scopus subject areas
- Clinical Biochemistry
Cite this
GST-P1 as a histological biomarker of synovial sarcoma revealed by proteomics. / Suehara, Yoshiyuki; Kikuta, Kazutaka; Nakayama, Turrent Robert; Tochigi, Naobumi; Seki, Kunihiko; Ichikawa, Hitoshi; Fujii, Kiyonaga; Hasegawa, Tadashi; Shimoda, Tadakazu; Kurosawa, Hisashi; Chuman, Hirokazu; Beppu, Yasuo; Kawai, Akira; Hirohashi, Setsuo; Kondo, Tadashi.
In: Proteomics - Clinical Applications, Vol. 3, No. 5, 2009, p. 623-634.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - GST-P1 as a histological biomarker of synovial sarcoma revealed by proteomics
AU - Suehara, Yoshiyuki
AU - Kikuta, Kazutaka
AU - Nakayama, Turrent Robert
AU - Tochigi, Naobumi
AU - Seki, Kunihiko
AU - Ichikawa, Hitoshi
AU - Fujii, Kiyonaga
AU - Hasegawa, Tadashi
AU - Shimoda, Tadakazu
AU - Kurosawa, Hisashi
AU - Chuman, Hirokazu
AU - Beppu, Yasuo
AU - Kawai, Akira
AU - Hirohashi, Setsuo
AU - Kondo, Tadashi
PY - 2009
Y1 - 2009
N2 - Synovial sarcoma have two histological subtypes, biphasic and monophasic, defined respectively by the presence or absence of glandular epithelial differentiation. To develop histological biomarkers for synovial sarcoma subtypes, we examined the proteomic profile using two-dimensional difference gel electrophoresis. We identified 29 protein spots whose intensity was statistically different between the monophasic (15 cases) and biphasic (9 cases) subtypes (p <0.01). Mass spectrometric protein identification demonstrated that these 29 spots corresponded to 24 distinct gene products involved in cytoskeletal organization, trsnscription/translation, protein/collagen binding, and ion transport, as well as structural constituents of the epidermis. Two of the 29 spots derived from glutathione S-transferase P (GST-P1) had higher intensity in biphasic type. Immunohistochemistry on additional 42 synovial sarcoma cases revealed that positive expression of GST-P1 was observed in 10 of 12 biphasic (83.3%), in 4 of 27 monophasic (14.8%) and in 1 of 3 poorly differentiated synovial sarcomas (p = 0.0002). Among the clinico-pathological parameters examined, GST-P1 expression significantly correlated only with the histological subtype. GST-P1 had more discriminative power than the status of fusion genes SYT-SSX1 and SYT-SSX2, previously reported to be correlated with the histological subtype. These results establish GST-P1 as a histological biomarker candidate for synovial sarcoma differentiation into subtypes.
AB - Synovial sarcoma have two histological subtypes, biphasic and monophasic, defined respectively by the presence or absence of glandular epithelial differentiation. To develop histological biomarkers for synovial sarcoma subtypes, we examined the proteomic profile using two-dimensional difference gel electrophoresis. We identified 29 protein spots whose intensity was statistically different between the monophasic (15 cases) and biphasic (9 cases) subtypes (p <0.01). Mass spectrometric protein identification demonstrated that these 29 spots corresponded to 24 distinct gene products involved in cytoskeletal organization, trsnscription/translation, protein/collagen binding, and ion transport, as well as structural constituents of the epidermis. Two of the 29 spots derived from glutathione S-transferase P (GST-P1) had higher intensity in biphasic type. Immunohistochemistry on additional 42 synovial sarcoma cases revealed that positive expression of GST-P1 was observed in 10 of 12 biphasic (83.3%), in 4 of 27 monophasic (14.8%) and in 1 of 3 poorly differentiated synovial sarcomas (p = 0.0002). Among the clinico-pathological parameters examined, GST-P1 expression significantly correlated only with the histological subtype. GST-P1 had more discriminative power than the status of fusion genes SYT-SSX1 and SYT-SSX2, previously reported to be correlated with the histological subtype. These results establish GST-P1 as a histological biomarker candidate for synovial sarcoma differentiation into subtypes.
KW - 2-D DIGE
KW - GST-P1
KW - Proteomics
KW - Synovial sarcoma
UR - http://www.scopus.com/inward/record.url?scp=67649452101&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67649452101&partnerID=8YFLogxK
U2 - 10.1002/prca.200800211
DO - 10.1002/prca.200800211
M3 - Article
AN - SCOPUS:67649452101
VL - 3
SP - 623
EP - 634
JO - Proteomics - Clinical Applications
JF - Proteomics - Clinical Applications
SN - 1862-8346
IS - 5
ER -